Senti Biosciences Holdings, Inc. (SNTI)
0.2239
0.00 (0.00%)
USD |
NASDAQ |
Oct 19, 16:00
0.22
0.00 (0.00%)
After-Hours: 20:00
Senti Biosciences Holdings Enterprise Value : 20.77M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 20.77M |
| October 15, 2026 | 21.91M |
| October 14, 2026 | 21.26M |
| October 13, 2026 | 21.70M |
| October 12, 2026 | 23.69M |
| October 09, 2026 | 23.55M |
| October 08, 2026 | 23.78M |
| October 07, 2026 | 24.04M |
| October 06, 2026 | 23.82M |
| October 05, 2026 | 24.51M |
| October 02, 2026 | 23.80M |
| October 01, 2026 | 23.87M |
| September 30, 2026 | 23.49M |
| September 29, 2026 | 23.34M |
| September 28, 2026 | 23.42M |
| September 25, 2026 | 24.02M |
| September 24, 2026 | 24.45M |
| September 23, 2026 | 24.29M |
| September 22, 2026 | 23.59M |
| September 21, 2026 | 23.42M |
| September 18, 2026 | 23.73M |
| September 17, 2026 | 23.51M |
| September 16, 2026 | 23.46M |
| September 15, 2026 | 23.11M |
| September 14, 2026 | 23.17M |
| Date | Value |
|---|---|
| September 11, 2026 | 23.29M |
| September 10, 2026 | 23.11M |
| September 09, 2026 | 23.08M |
| September 08, 2026 | 23.60M |
| September 04, 2026 | 24.12M |
| September 03, 2026 | 24.39M |
| September 02, 2026 | 24.41M |
| September 01, 2026 | 24.35M |
| August 31, 2026 | 25.55M |
| August 28, 2026 | 25.50M |
| August 27, 2026 | 25.52M |
| August 26, 2026 | 25.80M |
| August 25, 2026 | 25.94M |
| August 24, 2026 | 25.54M |
| August 21, 2026 | 25.87M |
| August 20, 2026 | 27.34M |
| August 19, 2026 | 28.18M |
| August 18, 2026 | 27.16M |
| August 17, 2026 | 27.16M |
| August 14, 2026 | 27.75M |
| August 13, 2026 | 25.72M |
| August 12, 2026 | 25.45M |
| August 11, 2026 | 24.89M |
| August 10, 2026 | 24.63M |
| August 07, 2026 | 24.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 9.949M |
| Summit Therapeutics, Inc. | 10.93B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | -2.670M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.75M |
| Revenue (Quarterly) | 0.017M |
| Total Expenses (Quarterly) | 12.77M |
| EPS Diluted (Quarterly) | -0.4094 |
| Gross Profit Margin (Quarterly) | -3.82K% |
| Profit Margin (Quarterly) | -75.00K% |
| Earnings Yield | -788.4% |
| Normalized Earnings Yield | -802.86 |